Rapid Dose Therapeutics and McMaster University’s COVID-19 Vaccine Study Receives NSERC Research and Development Grant

CANNANNEW REPORT

BURLINGTON, Ontario–(BUSINESS WIRE)–$DOSE–Today, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) and McMaster University (“McMaster”) are pleased to announce that the ongoing development of an orally delivered vaccine candidate for COVID-19 has received the final installment of the Collaborative Research and Development grant, with a value of $120,000, from the Natural Sciences and Engineering Research Council of Canada (NSERC). “We appreciate the ongoing support received from the Canadian government through NSERC as we continue to drive this important research forward,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “Global experts have called for a needle-free method of delivering vaccines for COVID-19 and many other diseases, and this research is paramount to supporting the commercialization of such an innovation.” McMaster University research team lead Dr. Alex Adronov, PhD adds, “This installment allows us to continue our efforts in creating oral thin-film therapeutics for a variety of applications, including incorporation of vaccine components for needle-free vaccination.” The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 at this time. About Rapid Dose Therapeutics Corp. Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient. http://www.rapid-dose.com CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”,…

Excerpt only …
READ MORE BELOW
Source : Rapid Dose Therapeutics and McMaster University’s COVID-19 Vaccine Study Receives NSERC Research and Development Grant

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.